Abstract Coronavirus disease 2019 (COVID-19)-associated invasive fungal infections are an
important complication in a substantial number of critically ill, hospitalized patients with …

During recent decades, the emergence of pathogenic fungi has posed an increasing public
health threat, particularly given the limited number of antifungal drugs available to treat …

The epidemiology of invasive fungal infections is changing, with new populations at risk and
the emergence of resistance caused by the selective pressure from increased usage of …

Background Mucormycosis, a rare fungal infection, has shown an increase in the number of
reported cases during the COVID-19 pandemic. Objectives To provide a comprehensive …

Coronavirus disease 19 (COVID-19)-associated pulmonary aspergillosis (CAPA) is a severe
fungal infection complicating critically ill COVID-19 patients. Numerous retrospective and …

Background Influenza-associated pulmonary aspergillosis (IAPA) and COVID-19-associated
pulmonary aspergillosis (CAPA) affect about 15% of critically ill patients with influenza or …

Background Recent multicenter studies identified COVID-19 as a risk factor for invasive
pulmonary aspergillosis (IPA). However, no large multicenter study has compared the …

SARS-CoV-2 infection causes COVID-19 disease, which can result in consequences
ranging from undetectable to fatal, focusing attention on the modulators of outcomes. The …

First reports of cases and case series of COVID-19-associated pulmonary aspergillosis
(CAPA) emerged during the first months of the pandemic. Prevalence rates varied widely …

Background Critically ill COVID-19 patients are highly susceptible to opportunistic fungal
infection due to many factors, including virus-induced immune dysregulation, host-related …